Abstract
Background
Advances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but current US population‐based epidemiologic data are lacking. This study aimed to estimate temporal trends and current prevalence and incidence of ATTR‐CM in the United States and to describe patient characteristics and the clinical burden.
Methods
Data from the US Merative MarketScan Medicare Database (2010–2021) and the IQVIA PharMetrics Plus (2016–2023) claims database were assessed. An algorithm using codes for diagnoses and clinical drugs was used to identify patients with ATTR‐CM among individuals ≥18 years old. Incidence, prevalence, demographics, comorbidities, medication use, and clinical encounters were assessed annually in cross‐sectional cohorts.